Abstract: Objective To explore the clinical efficacy of tiopronin combined with entecavir in the treatment of patients with chronic hepatitis B with focus on serum liver function and liver fibrosis index. Methods 116 patients with chronic hepatitis B admitted to our hospital between June 2015 and June 2016 were recruited,and were randomly divided into control group and observation group,with 58 cases in each group. Serum liver function,liver fibrosis index,and serologic and virologic markers were detected routinely. Results At the end of three month treatment,serum ALT level in the observation group was（41.2±11.7） U/L,which was significantly lower than that in the control group（49.7±12.4） U/L,P<0.01）,AST level was（37.2±25.2） U/L,which was significantly lower than that in the control group[（51.3±30.2） U/L,P<0.01）,the levels of ALB was（35.2±2.5） g/L,not significantly different as compared with that in the control;serum level of HA was（93.9±4.2） μg/L,which was significantly lower than that in the control group [（103.6±35.1） μg/L,P<0.01],serum level of LN was （103.6±38.2） μg/L,which was significantly lower than that in the control group[（127.9±40.5） μg/L,P<0.01],serum level of C-IV was（105.2±40.3） μg/L,which was significantly lower than that in the control group [（133.8±35.1） μg/L,P<0.01）,and serum level of PCIII was（75.3±16.7） μg/L,which was significantly lower than that in the control group [（91.2±18.5） μg/L,P<0.05）];serum negative rates of HBV DNA in the two groups were 60.3% vs. 60.3%（P>0.05） and no serum HBsAg or HBeAg negativity occurred in the two groups;there was no severe side effects in both groups. Conclusion The clinical efficacy of tiopronin combined with entecavir in the treatment of patients with chronic hepatitis B is significant,especially on the improvement of liver function and liver fibrosis index,and the therapy is safe.

Key words: Chronic hepatitis B, Tiopronin, Entecavir, Efficacy